Sylvie Rottey

12.2k total citations · 4 hit papers
236 papers, 7.9k citations indexed

About

Sylvie Rottey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sylvie Rottey has authored 236 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Oncology, 102 papers in Pulmonary and Respiratory Medicine and 51 papers in Molecular Biology. Recurrent topics in Sylvie Rottey's work include Cancer Immunotherapy and Biomarkers (46 papers), Renal cell carcinoma treatment (29 papers) and Lung Cancer Treatments and Mutations (23 papers). Sylvie Rottey is often cited by papers focused on Cancer Immunotherapy and Biomarkers (46 papers), Renal cell carcinoma treatment (29 papers) and Lung Cancer Treatments and Mutations (23 papers). Sylvie Rottey collaborates with scholars based in Belgium, United States and France. Sylvie Rottey's co-authors include Andrzej Kawecki, Ricardo Hitt, Ricard Mesı́a, Éva Remenár, Marco Benasso, Carsten Bokemeyer, D. De Raucourt, Didier Cupissol, Fernando Rivera and Nadia Amellal and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Sylvie Rottey

219 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 2.6k citations Sylvie Rottey et al. profile →
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

2019 400 citations Víctor Moreno, Christian Rolfo et al. profile →
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

2013 314 citations Sylvie Rottey et al. profile →
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib

2018 306 citations Axel Bex, Sylvie Rottey et al. profile →

Peers

Countries citing papers authored by Sylvie Rottey

Since Specialization

Citations

This map shows the geographic impact of Sylvie Rottey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Rottey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Rottey more than expected).

Fields of papers citing papers by Sylvie Rottey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvie Rottey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Rottey. The network helps show where Sylvie Rottey may publish in the future.

Co-authorship network of co-authors of Sylvie Rottey

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvie Rottey. A scholar is included among the top collaborators of Sylvie Rottey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvie Rottey. Sylvie Rottey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PET and SPECT Imaging of Macrophages in the Tumor Stroma: An Update 2025 ·Journal of Clinical Medicine ·Shaobo Li, Alex Maes, Tijl Vermassen, (unknown), (unknown), Sylvie Rottey, Christophe Van de Wiele	0
2	Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study 2025 ·European Journal of Cancer ·Viktor Grünwald, Axel Bex, Sylvie Rottey, (unknown), Giuseppe Procopio, Guillermo Velasco, Bohuslav Melichar, Jens Bedke, Lisa Pickering, (unknown), Manuela Schmidinger, Aristotelis Bamias, Marine Gross‐Goupil, Camillo Porta, Philippe Barthélémy, (unknown), Laurence Albigès	1
3	Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study 2025 ·Clinical Cancer Research ·Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado, Takeo Kosaka, Walter M. Stadler, Lisa G. Horvath, Richard Greil, Bert H. O’Neil, Bilal A. Siddiqui, Thomas Bauernhofer, Mehmet Asım Bilen, Ferry A.L.M. Eskens, Shahneen Sandhu, Crystal Shaw, Chia Hsin Ju, Benjamin E. Decato, (unknown), Ana M. Aparicio	0
4	Safety and Pharmacokinetics of MK ‐8527 in Adults Without HIV 2025 ·Clinical and Translational Science ·(unknown), Russ P. Carstens, (unknown), (unknown), Yash Kapoor, (unknown), Jean‐François Denef, Tom Reynders, Frédéric Vanhoutte, Sylvie Rottey, Randolph P. Matthews, S. Aubrey Stoch, Marian Iwamoto	0
5	Retrospective analysis of multiparametric MRI in predicting complete pathologic response of neo-adjuvant chemotherapy in bladder cancer 2024 ·BMC Medical Imaging ·Daan De Maeseneer, Pieter De Visschere, (unknown), (unknown), Geert Villeirs, Sofie Verbeke, Valérie Fonteyne, Charles Van Praet, Karel Decaestecker, (unknown), Sylvie Rottey	1
6	Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab. 2024 ·Journal of Clinical Oncology ·Chrisann Kyi, (unknown), Sylvie Rottey, Ignacio Melero, Diana Mittag, (unknown), Kees Bol, (unknown), Andrew K. Joe, Gianluca Laus, Víctor Moreno	4
7	Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours 2023 ·European Journal of Cancer ·Patrick Schöffski, Jean‐Pascal Machiels, Sylvie Rottey, (unknown), Hanny Musa, Kristell Marzin, Ahmad Awada	10
8	181P GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative 2023 ·Annals of Oncology ·Philippe Aftimos, Kevin Punie, Lore Decoster, Cédric van Marcke, Aline Hébrant, Gordana Raicevic, Els Van Valckenborgh, Brigitte Maes, (unknown), Joëlle Collignon, (unknown), (unknown), Wim Demey, Sabine Tejpar, Marc Peeters, J-L. Canon, Willem Lybaert, Jeroen Mebis, Sylvie Rottey, Jacques De Grève	0
9	Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors 2022 ·EUR Research Repository (Erasmus University Rotterdam) ·Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, Jean‐Pascal Machiels, Ben Markman, Kimberley M. Heinhuis, Michael Millward, Martijn P. Lolkema, Sandip Pravin Patel, Paul de Souza, Matteo Duca, Giuseppe Curigliano, Armando Santoro, Takafumi Koyama, Michelle Brown, Heather Vezina, Chunsheng He, Quincy S. Chu	40
10	Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma 2021 ·SHILAP Revista de lepidopterología ·Charles Van Praet, (unknown), Nikhil Vasdev, Sylvie Rottey, Valérie Fonteyne, Iulia Andraș, Maarten Albersen, Gert De Meerleer, Axel Bex, Karel Decaestecker	16
11	Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial 2021 ·Nature Medicine ·Randolph P. Matthews, Munjal Patel, Stephanie E. Barrett, (unknown), Tom Reynders, (unknown), Sylvie Rottey, Adrian P. Goodey, (unknown), Jay A. Grobler, S. Aubrey Stoch, Marian Iwamoto	50
12	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors 2021 ·Clinical Cancer Research ·Matthew D. Hellmann, Nicoletta Bivi, Boris Calderón, Toshio Shimizu, (unknown), (unknown), Anna M. Szpurka, (unknown), F. Stephen Hodi, Sylvie Rottey, Philippe Aftimos, Yongzhe Piao, Leena Gandhi, Violeta Régnier Galvão, Ching Ching Leow, Toshihiko Doi	84
13	Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis 2021 ·European Journal of Cancer ·(unknown), Nele Brusselaers, Sylvie Rottey, (unknown), David Creytens, Lore Lapeire	74
14	Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures 2021 ·Cancers ·Annabel Meireson, Simon J. Tavernier, Sofie Van Gassen, Nora Sundahl, Annelies Demeyer, (unknown), Vibeke Krüse, Liesbeth Ferdinande, Jo Van Dorpe, Benjamin Hennart, Delphine Allorge, Filomeen Haerynck, Karel Decaestecker, Sylvie Rottey, Yvan Saeys, Piet Ost, Liève Brochez	4
15	A feasibility study on adaptive 18F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territory 2018 ·Strahlentherapie und Onkologie ·(unknown), Dirk Van Gestel, Dieter Berwouts, Werner De Gersem, (unknown), Wilfried De Neve, (unknown), (unknown), Sylvie Rottey, Tom Vercauteren, Ingeborg Goethals, Fréderic Duprez	8
16	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies 2017 ·Clinical Cancer Research ·Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean‐Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean‐Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans de Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, Ahmad Awada	47
17	The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies 2017 ·Urologic Oncology Seminars and Original Investigations ·Tom Claeys, Nicolaas Lumen, Candy Kumps, Marleen Praet, Gert De Meerleer, Sylvie Rottey, Piet Ost, (unknown), Geert Villeirs, Valérie Fonteyne, Karel Decaestecker	2
18	Preliminary Results of A Phase I/IIA Study of BMS-986156 (GLUCOCORTICOID-Induced Tumour Necrosis Factor Receptor-Related Gene [GITR] AGONIST), Alone and In Combination with Nivolumab in Patients with Advanced Solid Tumours 2017 ·Asia-Pacific Journal of Clinical Oncology ·Lillian L. Siu, Neeltje Steeghs, Tarek Meniawy, Markus Joerger, Jennifer L. Spratlin, Sylvie Rottey, Adnan Nagrial, Adam Cooper, Roland Meier, Yun Shen, Penny Phillips, Gaurav Bajaj, Jochem Gokemeijer, Alan J. Korman, Kyaw Aung, Matteo S. Carlino	1
19	Prolonged survival in a nasopharyngeal carcinoma (NPC) patient with metastatic disease : a case report 2015 ·Ghent University Academic Bibliography (Ghent University) ·Astrid De Meulenaere, Philippe Deron, Fréderic Duprez, Liesbeth Ferdinande, Luc Verbeke, (unknown), Sylvie Rottey	0
20	Opioid use in the last 24 hours of life. A large-scale retrospective survey among Belgian physicians 2014 ·Palliative Medicine ·Kenneth Chambaere, Daan De Maeseneer, Sylvie Rottey, Joachim Cohen, Simon Van Belle, Robert Vander Stichele, Luc Deliëns	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact